Literature DB >> 10340688

The role of typical and atypical antipsychotic medications in the management of agitation and aggression.

P F Buckley1.   

Abstract

The management of agitation and aggression in psychiatric inpatients is a significant clinical dilemma. Establishing a clear diagnosis and distinguishing whether aggression is an acute manifestation or a long-standing or repetitive problem are fundamental antecedents of medication treatment. For acute aggression, either benzodiazepines or antipsychotic medications (typical and atypical) are recommended choices. Currently, on the basis of efficacy, ease of use, and availability in multiple (tablet, liquid, intramuscular) preparations, typical antipsychotics such as loxapine should be considered as first choice for acute aggression (in psychosis). On the other hand, atypical antipsychotics, particularly clozapine, should be considered when aggression in psychosis persists and/or is repetitive. Typical antipsychotics are indicated for persistent aggression in psychosis when medication noncompliance is the obstacle to effective treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340688

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour.

Authors:  G Gobbi; L Pulvirenti
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

Review 2.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 3.  Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.

Authors:  Margo D M Faay; Pál Czobor; Iris E C Sommer
Journal:  Neuropsychopharmacology       Date:  2018-07-23       Impact factor: 7.853

Review 4.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Intramuscular olanzapine: a review of its use in the management of acute agitation.

Authors:  Antona J Wagstaff; Jane Easton; Lesley J Scott
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.

Authors:  James P Burkett; Larry J Young
Journal:  Psychopharmacology (Berl)       Date:  2012-08-11       Impact factor: 4.530

7.  Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Richard A Van Dorn; Jan Volavka; John Monahan; T Scott Stroup; Joseph P McEvoy; H Ryan Wagner; Eric B Elbogen; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

8.  Violence and mental illness.

Authors:  Marie E Rueve; Randon S Welton
Journal:  Psychiatry (Edgmont)       Date:  2008-05

Review 9.  The physician's unique role in preventing violence: a neglected opportunity?

Authors:  John C Umhau; Karysse Trandem; Mohsin Shah; David T George
Journal:  BMC Med       Date:  2012-11-23       Impact factor: 8.775

10.  Anti-aggressive effects of agonists at 5-HT1B receptors in the dorsal raphe nucleus of mice.

Authors:  Makoto Bannai; Eric W Fish; Sara Faccidomo; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-04-18       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.